GRÜNENTHAL GMBH

EXECUTIVE BOARD

Beatriz Balbin Chief Special Procedures Branch OHCHR

Subject:

Joint Communication from Special Procedures

Reference:

AL OTH 196/2021

24 June 2021

Dear Ms. Balbin,

We refer to the Joint Communication from the Special Procedures mandate holders dated 7 June 2021 (the "*Joint Communication*"). We note the Special Procedures' request for information related to the reproductive health of women and girls in Chile.

Grünenthal's mission is to improve the quality of people's lives by developing and distributing pharmaceutical products in line with the highest scientific and ethical standards. We have served healthcare professionals and patients in Chile for over 40 years, contributing to the health and well-being of millions of Chileans.

As part of our mission, we continue to provide access to safe and effective oral contraceptives to women and their physicians in Chile, including in areas of greater socioeconomic deprivation. Patient safety is our highest priority, and we apply strict pharmacovigilance and quality management systems to our products.

Grünenthal values the important mandate given by the Human Rights Council to the Special Procedures not only to report and advise on human rights, but also to ascertain full and accurate facts with respect to the specific allegations contained in the Joint Communication.

Accordingly, we shall respond as expeditiously and comprehensively as possible to your request for information within 60 days, after which we understand the communication and any response is to be made public.

We assure you of our highest consideration.

Yours sincerely,

Gabriel Baertschi

CEO

Chairman of the Supervisory Board Prof. Dr. Wilhelm Moll LL.M.

Executive Directors Gabriel Baertschi (Chairman), Dr. Jan Adams, Mark Fladrich, Fabian Raschke
Registered office Aachen Registration code Amtsgericht Aachen, HRB Nr. 3546

Address for correspondence Grünenthal GmbH, 52099 Aachen, Germany www.grunenthal.com